Cargando…
Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity
Class I histone deacetylases (HDACs) are key regulators of cell proliferation and they are frequently dysregulated in cancer cells. We report here the synthesis of a novel series of class-I selective HDAC inhibitors (HDACi) containing a 2-aminobenzamide moiety as a zinc-binding group connected with...
Autores principales: | Ibrahim, Hany S., Abdelsalam, Mohamed, Zeyn, Yanira, Zessin, Matthes, Mustafa, Al-Hassan M., Fischer, Marten A., Zeyen, Patrik, Sun, Ping, Bülbül, Emre F., Vecchio, Anita, Erdmann, Frank, Schmidt, Matthias, Robaa, Dina, Barinka, Cyril, Romier, Christophe, Schutkowski, Mike, Krämer, Oliver H., Sippl, Wolfgang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745332/ https://www.ncbi.nlm.nih.gov/pubmed/35008795 http://dx.doi.org/10.3390/ijms23010369 |
Ejemplares similares
-
Docking, Binding Free Energy Calculations and In Vitro Characterization of Pyrazine Linked 2-Aminobenzamides as Novel Class I Histone Deacetylase (HDAC) Inhibitors
por: Bülbül, Emre F., et al.
Publicado: (2022) -
Application of Ligand- and Structure-Based Prediction Models for the Design of Alkylhydrazide-Based HDAC3 Inhibitors as Novel Anti-Cancer Compounds
por: Bülbül, Emre F., et al.
Publicado: (2023) -
Continuous Activity Assay for HDAC11 Enabling Reevaluation
of HDAC Inhibitors
por: Kutil, Zsófia, et al.
Publicado: (2019) -
Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis
por: Ghazy, Ehab, et al.
Publicado: (2022) -
Binding Free Energy (BFE) Calculations and Quantitative Structure–Activity Relationship (QSAR) Analysis of Schistosoma mansoni Histone Deacetylase 8 (smHDAC8) Inhibitors
por: Simoben, Conrad V., et al.
Publicado: (2021)